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related cost-effectiveness studies on diabetes. METHODS: A
literature search using PubMed and OhioLINK websites was
conducted for cost-effectiveness studies. The key terms used for
literature search were “diabetes”, and “cost, cost-effectiveness,
cost-beneﬁt, economics, or treatment outcome”. Eligible studies
were randomized controlled trials focusing cost-effectiveness of
diabetes drug therapies, published in English between July 2005
and October 2007. Review articles were excluded. RESULTS:
Initial search resulted in 911 abstracts. After applying the
inclusion/exclusion criteria, 11 studies were selected from
Canada, UK, USA, Austria, Germany and Asian regions. The
median sample size was 638 patients; the median duration of
trials was 39 weeks. Most studies demonstrated overall positive
effects in economic outcomes and found that interventions
improved the cost-effectiveness and health care utilization over
the control groups from their individual perspectives. Four
studies focused on insulin glargine, which together with other
new drugs including insulin detemir, exenatide and rosiglita-
zone can be more cost-effective. With regard to diabetes-related
complications such as renal disease, hypertension and diabetic
peripheral neuropathic pain, these studies suggest that the
earlier introduction of preventive measures such as therapeutic
drugs would lead to longer delays in the onset of its compli-
cations and the overall savings in health care resource utiliza-
tion. CONCLUSION: There is growing evidence that these
drug interventions may promote diabetic health with better
economic outcomes. The review complemented our previous
study of cost on diabetes till July 2005. Future research should
include extensive database search including databases such as
Cochran and manual search for the journals’ Diabetes, and
Diabetes Care.
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OBJECTIVE: Bradycardia-tachycardia syndrome (BTS) manage-
ment includes bradycardia and tachyarrhythmia therapy. Right
atrial appendage pacing (RAA), a typical pacing site, manages
bradycardia but have poor AF preventive properties. Biatrial
pacing (BiA) is a modality of pacing to prevent AF in BRT
patients with interatrial conduction disturbances. It is a cost-
effectiveness analysis of BiA versus RAA pacing in AF preven-
tion, in BTS patients. METHODS: Follow-up study: 125 pts (51
males, mean age = 67.9) with BTS, P-wave >120 ms and parox-
ysmal, recurrent AF; 50 pts had BiA and 75 RAA pacing system
implanted. Observation window was one year before pacemaker
implantation to three years after. Costs were calculated from the
public health care payer perspective. Primary clinical endpoints:
chronic AF occurrence and patient reported outcome reﬂecting
symptomatic AF episodes frequency at four point scale. AF epi-
sodes were deﬁned very frequent in case of AF episodes >1 per
week (rank 3), recurrent AF = 1 episode per week to 1 episode
per month (rank 2), occasional = if occurred <1 per month (rank
1), no recurrences = rank 0. Conﬁdence intervals for CER by
bootstrap method. RESULTS: The frequency of symptomatic AF
episodes decreased in BiA group as measured on the scale (2.54
vs 1.28; p < 0.001) and not in the RAA group (1.33 vs 1.55; NS).
There was 71.2% reduction of annual number of hospitaliza-
tions in BiA group; no change in RAA group as compared to
pre-implantation period. In BiA group 12.0% of patients devel-
oped chronic AF; 17.3% in the RAA group (NS). Incremental
cost-effectiveness ratio for decrease of AF frequency episodes
(BiA vs RAA) was 499.97 USD PPP (95%CI—272.5–1353.6) for
one point on the scale. CONCLUSION: Biatrial pacing in
contrast to RAA pacing decreases symptomatic AF episodes
frequency and hospitalizations. BiA compared to RAA pacing is
a cost-effective method of AF prevention in BTS patients with
pacing indications.
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OBJECTIVE: To assess whether bosentan is a cost-effective
ﬁrst-line treatment option compared with epoprostenol and
with no active intervention, all added to palliative care, for
patients with pulmonary arterial hypertension (PAH) of WHO
functional class (FC) III in the UK. METHODS: A cost-utility
model was constructed to simulate hypothetical patients with
PAH. Patients were assumed either to remain in FC III until
death or to deteriorate to FC IV where epoprostenol and pal-
liative care would be prescribed until death. It was further
assumed that the choice of ﬁrst-line treatment would not affect
the time to death, but instead would affect the duration patients
spend in FC IV. The time to deterioration in FC was approxi-
mated by time to clinical worsening (TTCW), a composite
measure of death or worsening of PAH leading to a change in
treatment. Data on TTCW was estimated from over three years
of observational data for bosentan and from published epide-
miological literature for palliative care alone. For epoprostenol,
TTCW was assumed equal to that of bosentan—in accordance
with published literature. The time horizon was that of patient
lifetime with only direct medical costs considered. The utility
associated with each FC was taken from published literature.
Costs and beneﬁts were discounted at 3.5% per annum. Proba-
bilistic sensitivity analyses were undertaken. RESULTS: Bosen-
tan dominated epoprostenol, as it provided the same number of
QALYs at a reduced cost. Bosentan dominated no active inter-
vention, as it had lower costs and greater QALYs, due to the
reduced time, per patient, spent in FC IV. CONCLUSION:
Bosentan is a more cost-effective ﬁrst-line therapy for patients
with PAH FC III in the UK than either epoprostenol or no active
intervention. It can be inferred that bosentan would also domi-
nate any other intervention with a TTCW not proven to be
better than palliative care alone.
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OBJECTIVE: To estimate differences in the efﬁcacy and safety of
rivaroxaban versus fondaparinux, warfarin and dabigatran in
prevention of venous thromboembolism (VTE). Such differences
may inﬂuence the cost-effectiveness of thromboprophylaxis
following total hip replacement (THR) or total knee replacement
(TKR). METHODS: Three large, randomized controlled trials
(RCTs; RECORD1–3) demonstrated relative risk reductions
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